Search

Your search keyword '"Irie, Tetsumi"' showing total 168 results
Start Over Author "Irie, Tetsumi" Search Limiters Peer Reviewed
168 results on '"Irie, Tetsumi"'

1. Intracerebroventricular 2-hydroxypropyl-γ-cyclodextrin alleviates hepatic manifestations without distributing to the liver in a murine model of Niemann–Pick disease type C

Author

Yamada, Yusei, Ishitsuka, Yoichi, Fukaura-Nishizawa, Madoka, Kawata, Tatsuya, Ishii, Akira, Shirakawa, Aina, Sakai, Taichi, Tanaka, Mayuko, Kondo, Yuki, Takeo, Toru, Nakagata, Naomi, Motoyama, Keiichi, Higashi, Taishi, Arima, Hidetoshi, Seki, Takahiro, Kurauchi, Yuki, Katsuki, Hiroshi, Higaki, Katsumi, Ikeda, Ryuji, Matsuo, Muneaki, Era, Takumi, and Irie, Tetsumi

Published
2024
Full Text
View/download PDF

4. Fine-tuned cholesterol solubilizer, mono-6-O-α-D-maltosyl-γ-cyclodextrin, ameliorates experimental Niemann–Pick disease type C without hearing loss

Author

Yamada, Yusei, Miwa, Toru, Nakashima, Masaki, Shirakawa, Aina, Ishii, Akira, Namba, Nanami, Kondo, Yuki, Takeo, Toru, Nakagata, Naomi, Motoyama, Keiichi, Higashi, Taishi, Arima, Hidetoshi, Kurauchi, Yuki, Seki, Takahiro, Katsuki, Hiroshi, Okada, Yasuyo, Ichikawa, Atsushi, Higaki, Katsumi, Hayashi, Ken, Minami, Kentaro, Yoshikawa, Naoki, Ikeda, Ryuji, Ishikawa, Yoshihide, Kajii, Tomohito, Tachii, Kyoko, Takeda, Hiroki, Orita, Yorihisa, Matsuo, Muneaki, Irie, Tetsumi, and Ishitsuka, Yoichi

Published
2022
Full Text
View/download PDF

6. Efficient breeding system of infertile Niemann–Pick disease type C model mice by in vitro fertilization and embryo transfer.

Author

Kuroshima, Serina, Nakao, Satohiro, Horikoshi, Yuka, Ito, Kotono, Ishii, Akira, Shirakawa, Aina, Kondo, Yuki, Irie, Tetsumi, Ishitsuka, Yoichi, Nakagata, Naomi, and Takeo, Toru

Subjects
FERTILIZATION in vitro, EMBRYO transfer, IN vitro studies, GENETIC mutation, TRANSLATIONAL research
Abstract

Copyright of Laboratory Animals is the property of Sage Publications, Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

13. The exacerbating roles of CCAAT/enhancer-binding protein homologous protein (CHOP) in the development of bleomycin-induced pulmonary fibrosis and the preventive effects of tauroursodeoxycholic acid (TUDCA) against pulmonary fibrosis in mice

Author

Tanaka, Yuta, Ishitsuka, Yoichi, Hayasaka, Marina, Yamada, Yusei, Miyata, Keishi, Endo, Motoyoshi, Kondo, Yuki, Moriuchi, Hiroshi, Irikura, Mitsuru, Tanaka, Ken-ichiro, Mizushima, Tohru, Oike, Yuichi, and Irie, Tetsumi

Published
2015
Full Text
View/download PDF

25. Japanese Pharmacists' Perceptions of Self-Development Skills and Continuing Professional Development.

Author

Mamiya, Kayoko Takeda, Takahashi, Kiyoshi, Iwasaki, Tatsuyuki, and Irie, Tetsumi

Subjects
CAREER development, PHARMACISTS' attitudes, PHARMACIST-patient relationships, CONTINUING education, MEDICAL personnel, UNDERGRADUATE education
Abstract

Background: The role of healthcare professionals, including pharmacists, is changing. Lifelong learning and continuing professional development (CPD) are more critical than ever for both current and future pharmacists in the face of global health challenges and new technologies, services and therapies that are continually and rapidly introduced into their daily practice. Currently, Japanese pharmacists' licences are not renewable, although most developed countries have a renewal system. Therefore, understanding Japanese pharmacists' perceptions of CPD is the first step in reviewing undergraduate and postgraduate education. Methods: The target population was Japanese pharmacists, i.e., community pharmacy pharmacists and hospital pharmacists. The participants were administered a questionnaire with 18 items related to continuing professional development. Results: Our study found that regarding item "Q16 Do you think you need further education in your undergraduate education to continue your professional development?", (a) the ability to identify one's own problems and issues, (b) the ability to make plans to solve problems and issues, (c) the ability to carry out plans to solve problems and issues and (d) the ability to repeat steps of self-development, approximately 60% of pharmacists answered that these aspects were "necessary" or "quite necessary". Conclusion: As part of universities' responsibility for the lifelong education of pharmacists, it is necessary to systematically conduct teaching seminars or undergraduate education or postgraduate education on self-development while training pharmacists to meet the needs of citizens. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Significance of Circulating Remnant Lipoprotein Cholesterol Levels Measured by Homogeneous Assay in Patients with Type 2 Diabetes.

Author

Matsushima-Nagata, Kazumi, Matsumura, Takeshi, Kondo, Yuki, Anraku, Kensaku, Fukuda, Kazuki, Yamanaka, Mikihiro, Manabe, Masahiro, Irie, Tetsumi, Araki, Eiichi, and Sugiuchi, Hiroyuki

Subjects
TYPE 2 diabetes, ANKLE brachial index, HDL cholesterol, LDL cholesterol, CHOLESTEROL, LOW density lipoproteins, LIPOPROTEIN A
Abstract

Remnant lipoproteins (RLs), which are typically present at high concentrations in patients with type 2 diabetes mellitus (T2DM), are associated with cardiovascular disease (CVD). Although an RL cholesterol homogeneous assay (RemL-C) is available for the measurement of RL concentrations, there have been no studies of the relationship between RemL-C and clinical parameters in T2DM. Therefore, we evaluated the relationships between RemL-C and CVD-related parameters in patients with T2DM. We performed a cross-sectional study of 169 patients with T2DM who were hospitalized at Kumamoto University Hospital. Compared with those with low RemL-C, those with higher RemL-C had higher fasting plasma glucose, homeostasis model assessment for insulin resistance (HOMA-R), total cholesterol, triglyceride, small dense low-density lipoprotein cholesterol (sdLDL-C), and urinary albumin-creatinine ratio; and lower high-density lipoprotein cholesterol, adiponectin, and ankle brachial pressure index (ABI). Multivariate logistic regression analysis showed that sdLDL-C and ABI were significantly and independently associated with high RemL-C. Although LDL-C was lower in participants with CVD, there was no difference in RemL-C between participants with or without CVD. Thus, RemL-C may represent a useful index of lipid and glucose metabolism, and that may be a marker of peripheral atherosclerotic disease (PAD) in male patients with T2DM. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Lactose-Appended Hydroxypropyl-β-Cyclodextrin Lowers Cholesterol Accumulation and Alleviates Motor Dysfunction in Niemann–Pick Type C Disease Model Mice.

Author

Nishida, Takumi, Yokoyama, Ryoma, Kubohira, Yuto, Maeda, Yuki, Takeo, Toru, Nakagata, Naomi, Takagi, Hiroki, Ishikura, Kandai, Yanagihara, Kazunori, Misumi, Shogo, Kishimoto, Naoki, Ishitsuka, Yoichi, Kondo, Yuki, Irie, Tetsumi, Soga, Minami, Era, Takumi, Onodera, Risako, Higashi, Taishi, and Motoyama, Keiichi

Published
2022
Full Text
View/download PDF

44. Improved Formula for Predicting Hemodialyzability of Intravenous and Oral Drugs.

Author

Murakami, Marina, Narita, Yuki, Urata, Motoki, Ichigi, Misato, Nakatani, Sakura, Kondo, Yuki, Ishitsuka, Yoichi, Irie, Tetsumi, and Hirata, Sumio

Subjects
ORAL medication, STANDARD deviations, MULTIPLE regression analysis, PROTEIN binding
Abstract

Background: The rate of drug removal by hemodialysis needs to be considered when designing drug dosage regimens for patients on hemodialysis. We previously developed a simplified equation to predict the removal rates of intravenously administered drugs by hemodialysis. Here, we addressed shortcomings of this equation and developed a more accurate equation that can also predict the removal rates of orally administered drugs. Methods: A total of 70 drugs with known pharmacokinetic and physical parameters and drug removal rates that were measured during hemodialysis in clinical cases were randomly assigned at a 4:1 ratio to a training data group or a test data group. A prediction equation was developed by performing stepwise multiple regression analyses using the training data (i.e., the removal rate by hemodialysis) as the objective variable and pharmacokinetic parameters as the explanatory variables. The equation was validated using the test data. Results: Multiple regression analyses revealed that molecular weight (MW), protein binding rate, and fraction excreted unchanged in urine relative to the volume of distribution (Vd) were independently correlated with the drug clearance rate (adjusted coefficient of determination, 0.83; p = 2.2e−16). The following equation was obtained: drug removal rate by hemodialysis (%) = −17.32 × [log (MW)] – 0.39 × [protein binding rate (%)] + 0.06 × [fraction excreted unchanged in urine (%)/Vd (L/kg)] + 83.34. Validation of the equation using the test data showed a very high correlation between predicted and measured reduction rate (R = 0.93, p = 1.87e−6). Mean error was −3.34 (95% confidence interval: −10.03, 3.35), mean absolute error was 9.59, and root mean square error was 16.48. Conclusion: The modified equation derived in this study using pharmacokinetic and physical parameters as variables precisely predicted the removal rates of both intravenous and oral drugs by hemodialysis. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

48. Ozagrel hydrochloride, a selective thromboxane A2 synthase inhibitor, alleviates liver injury induced by acetaminophen overdose in mice

Author

Tomishima Yoshiro, Ishitsuka Yoichi, Matsunaga Naoya, Nagatome Minako, Furusho Hirokazu, Irikura Mitsuru, Ohdo Shigehiro, and Irie Tetsumi

Subjects
Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Abstract Background Overdosed acetaminophen (paracetamol, N-acetyl-p-aminophenol; APAP) causes severe liver injury. We examined the effects of ozagrel, a selective thromboxane A2 (TXA2) synthase inhibitor, on liver injury induced by APAP overdose in mice. Methods Hepatotoxicity was induced to ICR male mice by an intraperitoneal injection with APAP (330 mg/kg). The effects of ozagrel (200 mg/kg) treatment 30 min after the APAP injection were evaluated with mortality, serum alanine aminotransferase (ALT) levels and hepatic changes, including histopathology, DNA fragmentation, mRNA expression and total glutathione contents. The impact of ozagrel (0.001-1 mg/mL) on cytochrome P450 2E1 (CYP2E1) activity in mouse hepatic microsome was examined. RLC-16 cells, a rat hepatocytes cell line, were exposed to 0.25 mM N-acetyl-p-benzoquinone imine (NAPQI), a hepatotoxic metabolite of APAP. In this model, the cytoprotective effects of ozagrel (1–100 muM) were evaluated by the WST-1 cell viability assay. Results Ozagel treatment significantly attenuated higher mortality, elevated serum alanine aminotransferase levels, excessive hepatic centrilobular necrosis, hemorrhaging and DNA fragmentation, as well as increase in plasma 2,3-dinor thromboxane B2 levels induced by APAP injection. Ozagrel also inhibited the hepatic expression of cell death-related mRNAs induced by APAP, such as jun oncogene, FBJ osteosarcoma oncogene (fos) and C/EBP homologous protein (chop), but did not suppress B-cell lymphoma 2-like protein11 (bim) expression and hepatic total glutathione depletion. These results show ozagrel can inhibit not all hepatic changes but can reduce the hepatic necrosis. Ozagrel had little impact on CYP2E1 activity involving the NAPQI production. In addition, ozagrel significantly attenuated cell injury induced by NAPQI in RLC-16. Conclusions We demonstrate that the TXA2 synthase inhibitor, ozagrel, dramatically alleviates liver injury induced by APAP in mice, and suggest that it is a promising therapeutic candidate for the treatment of APAP-induced liver injury.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results